Magenta Medical Ltd.

Magenta Medical Ltd. , based in Israel, develops advanced medical technologies specializing in self-expanding percutaneous mechanical circulatory support systems aimed at enhancing cardiac function for patients with severe heart conditions. Magenta Medical Ltd. is focused on designing innovative solutions for cardiac support, particularly in high-risk clinical settings.

Founded in 2012 in Israel, the company has successfully raised a total of USD 105. 00 mn in funding, with the most recent round occurring in July 2024, led by Novo Holdings and involving multiple other investors. The founder's history is not detailed publicly, and there are no mentions of subsidiaries. Magenta Medical has participated in 6 investment deals to date, underscoring its ongoing commitment to advancing cardiac care technologies.

Magenta Medical specializes in innovative medical technologies, primarily focusing on self-expanding percutaneous mechanical circulatory support systems. These products are designed to enhance cardiac function and support patients with severe heart conditions, particularly those undergoing high-risk procedures or experiencing acute heart failure. Their core clientele includes hospitals and specialized cardiac care centers, particularly in North America and Europe, where advanced medical technologies are in high demand. By addressing the urgent needs of patients and healthcare professionals alike, Magenta Medical aims to improve clinical outcomes and streamline patient management in cardiology.

Magenta Medical generates revenue through direct sales of its mechanical circulatory support systems to healthcare institutions and hospitals. The transaction structure typically involves B2B engagements, where the company establishes partnerships with medical facilities to supply its products. Revenue is primarily derived from these direct sales, with potential for ongoing maintenance and support services offered as part of the product package. Pricing plans for their flagship products, which are known for their advanced technology and reliability, are structured to reflect the value provided to healthcare providers in critical care settings.

By ensuring that their products meet the rigorous demands of cardiology specialists, Magenta Medical positions itself as a key player in the medical technology market, facilitating impactful transactions that enhance patient care. In July 2024, Magenta Medical Ltd. raised USD 105. 00 mn in venture funding, with plans to utilize this investment to advance its U.

S. clinical programs in multiple mechanical circulatory support indications. The company aims to secure the first FDA approval for its Elevate heart pump, which is a critical step in its product development strategy. Additionally, Magenta Medical is focused on expanding its presence in new geographic regions, targeting North America and Europe for enhanced market penetration.

The funding will support these initiatives, helping the company to further innovate and deliver its products to meet the needs of healthcare providers.